Table 1.
Characteristics of 44 dilated cardiomyopathy patients who underwent transplantation stratified by polymerase chain reaction viral status of explanted hearts
| Variables | With viral (n=14) | Without viral (n=30) | P |
|---|---|---|---|
| Age at HT, yrs | |||
| Range | 0.9-15.5 | 0.1-17.6 | 0.106 |
| Median | 10.4 | 2 | |
| Mean±SD | 9.0±6.3 | 5.6±6.2 | |
| Male, n (%) | 8 (57%) | 16 (53%) | 0.810 |
| Race, n (%) | |||
| Hispanic | 6 (43%) | 10 (33%) | 0.542 |
| African American | 4 (29%) | 8 (27%) | 0.879 |
| White | 4 (29%) | 12 (40%) | 0.465 |
| Ventilator use, n (%) | 2 (14%) | 7 (23%) | 0.490 |
| MCS, n (%) | 8 (57%) | 12 (40%) | 0.289 |
| PRA >10%, n (%) | 4 (29%) | 10 (33%) | 0.749 |
| CMV mismatch, n (%) | 3 (21%) | 12 (40%) | 0.226 |
| Induction therapy, n (%) | |||
| Basiliximab | 9 (64%) | 23 (77%) | 0.389 |
| ATG | 4 (29%) | 7 (23%) | 0.711 |
| DSA, n (%) | 6 (43%) | 11 (37%) | 0.697 |
| Adverse outcomes, n (%) | |||
| CAV | 9 (64%) | 13 (43%) | 0.197 |
| Rejection | 3 (21%) | 4 (13%) | 0.497 |
| Graft loss | 2 (14%) | 4 (13%) | 0.928 |
(HT=heart transplant; MCS=mechanical circulatory support, PRA=panel reactive antibody, CMV- cytomegalovirus; CAV=cardiac allograft vasculopathy, ATG=anti-thymocyte globulin)